Pravastatin

證據等級: L5

預測適應症: 9 個

Pravastatin: From Hypercholesterolemia to Homozygous Familial Hypercholesterolemia

One-Sentence Summary

Pravastatin is a HMG-CoA reductase inhibitor (statin) established for treating hypercholesterolemia and reducing cardiovascular risk. The TxGNN model predicts it may be effective for Homozygous Familial Hypercholesterolemia (HoFH), but the supporting evidence — 1 clinical trial (not testing pravastatin itself) and 13 publications (mostly on other statins or general FH context) — is indirect and does not yet establish efficacy of pravastatin alone in this population.

Quick Overview

Item	Content
Original Indication	Not documented in this Evidence Pack (`taiwan_regulatory.licenses` is empty); pravastatin is generally indicated for hypercholesterolemia/dyslipidemia
Predicted New Indication	Homozygous Familial Hypercholesterolemia (HoFH)
TxGNN Prediction Score	99.95%
Evidence Level	L3 (indirect/observational evidence only; no direct RCT of pravastatin in HoFH)
Norway Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack (flagged as a High-severity data gap, DG002). Based on general pharmacological knowledge, pravastatin is a HMG-CoA reductase inhibitor that lowers hepatic cholesterol synthesis and is used to manage hypercholesterolemia and reduce cardiovascular risk.

HoFH is characterized by near-complete absence of functional LDL receptors, which is mechanistically the pathway statins primarily rely on to lower LDL-C. This creates an important caveat: as noted in the repurposing rationale, statins have limited standalone efficacy in HoFH and are typically used only as background/adjunct therapy alongside PCSK9 inhibitors, ezetimibe, or LDL apheresis — not as monotherapy.

The single clinical trial identified (NCT03510715) actually tests alirocumab, not pravastatin, in pediatric HoFH, and is graded "C" relevance — useful only as disease-background context. The literature base is similarly indirect, consisting largely of reviews/guidelines on other statins (rosuvastatin, atorvastatin), ezetimibe, and general statin-in-FH systematic reviews, rather than pravastatin-specific HoFH data. The prediction is therefore mechanistically plausible as an adjunct but not well supported as a primary therapy signal.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT03510715	Phase 3	Completed	18	Evaluated alirocumab (not pravastatin) in children/adolescents with HoFH on top of background lipid-lowering therapy; relevant only as HoFH population/background-treatment context, not direct evidence for pravastatin.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31696945	2019	Systematic Review	Cochrane Database Syst Rev	Statins (including pravastatin) in children with FH; largely covers heterozygous FH, notes HoFH as the severe end of the spectrum.
28437620	2017	Clinical Guideline	Endocr Pract	AACE/ACE dyslipidemia management guideline; statins positioned as foundational therapy across FH severity.
28685504	2017	Systematic Review	Cochrane Database Syst Rev	Earlier version of the statins-in-FH-children Cochrane review.
31358055	2019	Preclinical	Stem Cell Res Ther	iPSC-derived LDLR-deficient hepatocyte model for FH; supports disease mechanism, not direct pravastatin efficacy.
15531000	2004	Review	Clin Ther	Rosuvastatin review noting HoFH as a treatment indication for statins as a class.
12269853	2002	Review	Drugs	Rosuvastatin review; reports rosuvastatin outperformed pravastatin on lipid profile in comparative trials.
9793596	1998	Review	Ann Pharmacother	Atorvastatin review (comparator statin, not pravastatin-specific).
14727947	2003	Review	Am J Cardiovasc Drugs	Ezetimibe review; relevant as a common combination partner with statins in severe FH.

Norway Market Information

No marketing authorizations were found for pravastatin in the Norwegian register — consistent with the reported "Not marketed" status and 0 total licenses in this Evidence Pack.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all marked as gaps in this Evidence Pack; DG001 flags the missing TFDA label as a Blocking gap that prevents a full S1 safety pre-assessment.)

Conclusion and Next Steps

Decision: Hold

Rationale:

Evidence for pravastatin specifically in HoFH is indirect (the only trial tests a different drug, alirocumab) and the mechanistic rationale itself flags limited standalone efficacy in HoFH due to near-absent LDL receptor function. Combined with a Blocking data gap on TFDA label safety information (DG001), the candidate is not ready to advance.

To proceed, the following is needed:

TFDA label PDF (warnings/contraindications) to clear the Blocking gap (DG001) and enable S1 safety review
DrugBank MOA data to confirm mechanistic rationale (DG002)
Direct clinical evidence on pravastatin (alone or as background therapy) specifically in confirmed HoFH patients
Clarification of intended use case: adjunct/background therapy alongside PCSK9i/ezetimibe/apheresis, rather than monotherapy positioning
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.